The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

The Calmer Co (ASX:CCO) has wrapped up FY25 with preliminary unaudited revenue surpassing $8 million, which marks the third year in a row the kava-selling company has posted upward-trending year-end results.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

“You can see that there’s a broader audience looking at the product and realising what kava can do for them,” The Calmer Co’s CCO, Matt Kowal, told HotCopper after the company shared their FY25 results today.

That has translated directly into strengthening revenues, and even more interestingly, Calmer Co has been “playing in just 40% of the markets.”

“We have a great opportunity to grow the business,” e-commerce chief Andy Burger added.

Join the discussion: See what HotCopper users are saying about The Calmer Co. and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

cco by the numbers
More From The Market Online
AIZ plane

Air NZ up +1%, for some reason, even after suspending FY26 guidance

It’s only seen around $185,000 in trades share hands on Tuesday, but for some reason, at least one investor has thrown money at
HotCopper Daily Market Trends Graphic

Tuesday’s HotCopper trends: American T&A, Telix Pharma, Imugene, and other daily topics | March 10

It’s been a bounce-back day for Australian shares, with yesterday’s bloodbath somewhat pared by +1.5% gains across the day on Trump’s “peace” boasts.

Dreadnought Resources kicks off drilling at Metzkes Find under ‘find more gold faster’ strategy

Dreadnought Resources is ramping up its "finding more gold faster" strategy at the Illaara project in…

EVE Health Group to target global markets with reformulated drugs

EVE Health Group will test global markets after successfully completing R&D work on several reformulated drug…